journal article·2018-12-26

Microfluidic Nanoassembly of Bioengineered Chitosan-Modified FcRn-Targeted Porous Silicon Nanoparticles @ Hypromellose Acetate Succinate for Oral Delivery of Antidiabetic Peptides

João P. Martins, Dongfei Liu, Flavia Fontana, Mónica P. A. Ferreira, Alexandra Correia, Silvia Valentino, Marianna Kemell, Karina Moslova, Ermei Mäkilä, Jarno Salonen, Jouni Hirvonen, Bruno Sarmento, Hélder A. Santos

ACS Applied Materials & Interfaces· Volume 10· Issue 51
Publisher page

Abstract

Microfluidics technology is emerging as a promising strategy in improving the oral delivery of proteins and peptides. Herein, a multistage drug delivery system is proposed as a step forward in the development of noninvasive therapies. Undecylenic acid-modified thermally hydrocarbonized porous silicon (UnPSi) nanoparticles (NPs) were functionalized with the Fc fragment of immunoglobulin G for targeting purposes. Glucagon-like peptide-1 (GLP-1) was loaded into the NPs as a model antidiabetic drug. Fc-UnPSi NPs were coated with mucoadhesive chitosan and ultimately entrapped into a polymeric matrix with pH-responsive properties by microfluidic nanoprecipitation. The final formulation showed a controlled and narrow size distribution. The pH-responsive matrix remained intact in acidic conditions, dissolving only in intestinal pH, resulting in a sustained release of the payload. The NPs presented high cytocompatibility and increased levels of interaction with intestinal cells when functionalized with the Fc fragment, which was supported by the validation of the Fc-fragment integrity after conjugation to the NPs. Finally, the Fc-conjugated NPs showed augmented GLP-1 permeability in an intestinal in vitro model. These results highlight the potential of microfluidics as an advanced technique for the preparation of multistage platforms for oral administration. Moreover, this study provides new insights on the potential of the Fc receptor transcytotic capacity for the development of targeted therapies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · Microfluidic and Capillary Electrophoresis Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Drug Sciences, Università degli Studi di Pavia, Viale Taramello 12, 27100 Pavia, Itália

Department of Physics and Astronomy, University of Turku, Turku FI-20014, Finland

CESPU—Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, 4585-116 Gandra, Portugal

Funding

Sigrid Jus?liuksen S??ti? · European Regional Development Fund · Funda??o para a Ci?ncia e a Tecnologia · H2020 European Research Council · Helsingin Yliopisto · Helsinki Institute of Life Science, Helsingin Yliopisto

References (55)

Show source-provided references
1. 10.1038/nnano.2012.16810.1038/nnano.2012.168 ↗
2. 10.1038/nature0505810.1038/nature05058 ↗
3. 10.1080/17425247.2018.144693610.1080/17425247.2018.1446936 ↗
4. 10.1002/adma.20140540810.1002/adma.201405408 ↗
5. 10.1016/j.pmatsci.2017.05.00110.1016/j.pmatsci.2017.05.001 ↗
6. 10.1038/nrd106710.1038/nrd1067 ↗
7. 10.1038/nrd103310.1038/nrd1033 ↗
8. 10.1079/PNS1969000710.1079/PNS19690007 ↗
9. 10.1046/j.1365-2567.1997.00326.x10.1046/j.1365-2567.1997.00326.x ↗
10. 10.1083/jcb.71.2.66610.1083/jcb.71.2.666 ↗
11. 10.1093/humrep/deh89610.1093/humrep/deh896 ↗
12. 10.1126/scitranslmed.300704910.1126/scitranslmed.3007049 ↗
13. 10.1016/j.pharmthera.2016.03.00710.1016/j.pharmthera.2016.03.007 ↗
14. 10.1038/s41598-018-19170-y10.1038/s41598-018-19170-y ↗
15. 10.1002/adma.20120065310.1002/adma.201200653 ↗
16. 10.1002/adhm.20120033510.1002/adhm.201200335 ↗
17. 10.1021/nn901657w10.1021/nn901657w ↗
18. 10.1039/C6TB01829G10.1039/C6TB01829G ↗
19. 10.1016/j.jconrel.2013.05.03610.1016/j.jconrel.2013.05.036 ↗
20. 10.1021/bm800276d10.1021/bm800276d ↗
21. 10.1016/j.biomaterials.2014.04.10410.1016/j.biomaterials.2014.04.104 ↗
22. 10.1016/j.biomaterials.2015.07.04510.1016/j.biomaterials.2015.07.045 ↗
23. 10.1002/smll.20180046210.1002/smll.201800462 ↗
24. 10.1002/jps.2099910.1002/jps.20999 ↗
25. 10.1007/s12274-014-0635-410.1007/s12274-014-0635-4 ↗
26. 10.1038/s41598-017-02672-610.1038/s41598-017-02672-6 ↗
27. 10.4103/2277-9175.19926410.4103/2277-9175.199264 ↗
28. Zhou Z.-Q. · Am. J. Transl. Res. · 2016 · 8 · 2926
29. 10.1016/j.ejpb.2012.10.00310.1016/j.ejpb.2012.10.003 ↗
30. 10.1016/j.ijpharm.2013.10.00310.1016/j.ijpharm.2013.10.003 ↗
31. 10.1038/nmeth.201910.1038/nmeth.2019 ↗
32. 10.1177/221106821456102510.1177/2211068214561025 ↗
33. 10.1021/mp800079310.1021/mp8000793 ↗
34. 10.1517/17425247.2013.82197810.1517/17425247.2013.821978 ↗
35. 10.1016/j.ijpharm.2009.03.02910.1016/j.ijpharm.2009.03.029 ↗
36. 10.1016/j.jcis.2012.03.02710.1016/j.jcis.2012.03.027 ↗
37. 10.1021/bm500795410.1021/bm5007954 ↗
38. 10.1155/2009/43938910.1155/2009/439389 ↗
39. 10.1016/j.ajps.2015.08.01110.1016/j.ajps.2015.08.011 ↗
40. 10.1016/j.ijbiomac.2006.03.02310.1016/j.ijbiomac.2006.03.023 ↗
41. 10.1016/j.tibtech.2012.08.00110.1016/j.tibtech.2012.08.001 ↗
42. 10.1016/j.pharmthera.2009.11.00110.1016/j.pharmthera.2009.11.001 ↗
43. 10.1016/S0168-8227(06)70021-310.1016/S0168-8227(06)70021-3 ↗
44. 10.1021/am403999q10.1021/am403999q ↗
45. 10.1016/j.jconrel.2012.03.01710.1016/j.jconrel.2012.03.017 ↗
46. 10.1016/j.immuni.2004.05.00710.1016/j.immuni.2004.05.007 ↗
47. 10.1007/s11095-013-1212-310.1007/s11095-013-1212-3 ↗
48. 10.1172/JCI696810.1172/JCI6968 ↗
49. 10.1016/j.bbamcr.2009.10.00710.1016/j.bbamcr.2009.10.007 ↗
50. 10.1016/j.lfs.2009.10.01210.1016/j.lfs.2009.10.012 ↗
51. 10.1016/j.mimet.2013.06.02710.1016/j.mimet.2013.06.027 ↗
52. 10.1021/acsbiomaterials.6b0069910.1021/acsbiomaterials.6b00699 ↗
53. 10.1002/(SICI)1520-6017(200001)89:1<63::AID-JPS7>3.0.CO;2-610.1002/(SICI)1520-6017(200001)89:1<63::AID-JPS7>3.0.CO;2-6 ↗
54. 10.1016/j.biomaterials.2014.07.02610.1016/j.biomaterials.2014.07.026 ↗
55. 10.4155/ppa.12.7510.4155/ppa.12.75 ↗